 |
Scale Text: Normal | Large |
Send Page to a Friend | Print Page |
About ISCM
>> Mission Statement
>> Statutes
>> Board
>> Support Us
Laboratory Research
>> Cardiovascular Disease
>> Cancer
>> Other Research
Research Archive
>> Cellular Health Research
>> Studies Worldwide
Health News
>> Natural Health
>> Business With Disease
>> Other News
>> News Archive
>> Newsletter
World Health
>> Who is WHO?
>> Stop Codex!
>> Defend DSHEA
>> Health for All
>> HOMEPAGE
Modulation of synovial fibroblast plasminogen activator and plasminogen activator inhibitor production by protein kinase C.Biochim Biophys Acta 1991 Nov 21;1097(4):283-8 Uhl J; Newton RC; Gross JL; Rommi W; Mochan E Phorbol myristate acetate (PMA) added to human synovial fibroblast cultures caused a dose-dependent increase in the production of plasminogen activator inhibitor-type 1 (PAI-1). In addition, PMA inhibited endogenous and interleukin-1 (IL-1) induced plasminogen activator (PA) activity, while increasing mRNA PAI-1 levels. Other protein kinase C (PKC) activators, mezerein and teleocidin B4, caused similar effects. The simultaneous addition of the PKC antagonists, H-7 or staurosporine, prevented the inhibition of PA activity by PMA. This study shows that activation of PKC inhibits PA and stimulates PAI production in human synovial fibroblasts. These results suggest that activation of PKC may play an important role in regulating increased PA production associated with joint destruction in rheumatoid arthritis (RA). |
